P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects.
Aim of the present study was to establish the safety and efficacy profile of prasugrel and ticagrelor in real-life acute coronary syndrome (ACS) patients with renal dysfunction. All consecutive patients from RENAMI and BLEEMACS registries were stratified according to estimated glomerular filtration rate (eGFR) lower or greater than 60mL/min/1.73m2. Death and myocardial infarction (MI) were the primary efficacy endpoints. Major bleedings (MB), defined as Bleeding Academic Research Consortium bleeding types 3 to 5, constituted the safety endpoint.19255 patients were enrolled. Mean age was 63 ± 12; 14892 (77.3%) were males. 2490 (12.9%) patients had chronic kidney disease (CKD), defined as eGFR<60mL/min/1.73m2. Mean follow-up was 13±5 months. Mortality was significantly higher in CKD patients (9.4% vs 2.6%, p < 0.0001), as well as the incidence of reinfarction (5.8% vs 2.9%, p < 0.0001) and MB (5.7% vs 3%, p < 0.0001). At Cox multivariable analysis, potent P2Y12 inhibitors significantly reduced the mortality rate (HR 0.82, 95% CI 0.54-0.96, p = 0.006) and the risk of reinfarction (HR 0.53, 95% CI 0.30-0.95, p = 0.033) in CKD patients as compared to clopidogrel. The reduction of risk of re-infarction was confirmed in patients with preserved renal function. Potent P2Y12 inhibitors did not increase the risk of MB in CKD patients (HR 1.00, 95% CI 0.59-1.68, p = 0.985). In ACS patients with CKD, prasugrel and ticagrelor are associated with lower risk of death and recurrent MI without increasing the risk of MB.